Written from the studies on PubMed, searched on 11 Nov 2026. Every number below comes from a study listed under Sources. The text was written by AI from these studies; each sentence names the studies it comes from.
What people read
Posts and adverts say that Mucuna pruriens, a tropical bean plant, can treat Parkinson's disease. The plant naturally contains levodopa, the main Parkinson's medicine, so the idea has some basis, but the studies are small and mostly short.
What has been studied
- 4In people4 randomised trials
- 15In animals
- 3Only in the lab
What the studies found
Mucuna pruriens has been tested in randomised trials in people with Parkinson disease.
Trials in people
A 2004 double-blind crossover trial gave single doses of Mucuna preparation or standard levodopa/carbidopa to 8 people with Parkinson's disease; the authors report a faster start of effect and a longer "on" time with 30 g of Mucuna. [1] A 2017 double-blind crossover trial in 18 people with advanced Parkinson's tested single doses of Mucuna powder against standard levodopa and placebo; the authors report that high-dose Mucuna gave a bigger motor improvement and longer "on" time than standard levodopa, with fewer side effects. [2] A 2018 pilot crossover trial in 14 people with advanced Parkinson's ran for 16 weeks; half of those on Mucuna stopped early because of stomach side effects or worsening movement. [3] In that 2018 trial, the people who tolerated Mucuna had results similar to levodopa/carbidopa on all measures, according to the authors. [3] A 2026 open-label trial in sub-Saharan Africa gave Mucuna powder or standard levodopa to 32 people not yet treated, for 12 months; the authors report similar results on quality of life, motor and non-motor symptoms. [4] In the 2026 trial, side effects were more frequent with Mucuna (56% against 37.5%), though the authors say this difference was not statistically significant. [4] All four trials were small, and the 2026 trial was open-label, meaning patients and doctors knew which treatment was given. [4][3][2][1]
Other studies in people
A 2025 case report describes a person with Parkinson's who developed dopamine dysregulation syndrome, a pattern of taking more dopamine medicine than needed, after using self-directed Mucuna alongside prescribed levodopa. [5] A 2026 lab analysis of five Mucuna supplements found their levodopa content was 66.2% to 82.7% of what the makers stated. [6]
Reviews
A 2025 systematic review of 5 trials with 108 people in total rated one study high quality, one with some concerns and three low quality; the authors report consistent symptom improvements despite differences between the Mucuna products used. [7] A 2026 clinic-based review says that properly processed Mucuna gave benefits similar to commercial levodopa in trials, but long-term safety data are scarce. [8] The same review links overuse and unsupervised self-treatment to dyskinesia (involuntary movements), dopamine dysregulation syndrome and psychiatric problems, and recommends use only within trials or neurologist-led plans. [8] A 2024 review calls Mucuna a possible low-cost option where levodopa medicines are hard to get, but urges caution until more long-term safety and efficacy data exist. [9]
In animals
In mice given the toxin MPTP, daily Mucuna extract improved movement, but did not restore dopamine-making proteins or nerve cells in the brain, the authors report. [10] In a 12-mouse rotenone model, both Mucuna and levodopa improved balance and smell tests and changed inflammation markers, according to the authors. [11] In a rat paraquat model, extract from boiled and fermented Mucuna seeds raised the number of dopamine nerve cells in one brain area, while extract from fresh seeds did not. [12] A 2026 rat study of Mucuna combined with selenium nanoparticles and chitosan reported better movement and antioxidant levels than plain Mucuna extract. [13]
In the lab
A lab study of a Mucuna extract with the levodopa mostly removed reported protective effects in mouse and human cells and in worm and fruit fly models. [14] A 2026 lab study found that traditional purification changed which chemicals were present in Mucuna, and flagged 51 compounds with reported toxicity links. [15] Computer modelling studies have suggested possible targets for Mucuna compounds, but these are predictions, not tests in people. [16]
What this means for you: A study in people is not proof that it helps you. Do not stop or change your medicines because of it. Ask your doctor before you start taking it.
Sources
- Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.2004 · J Neurol Neurosurg Psychiatry · Randomised trial
- Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study.2017 · Neurology · Randomised trial
- Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study.2018 · Parkinsonism Relat Disord · Randomised trial
- Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial.2026 · J Parkinsons Dis · Randomised trial
- Dopamine Dysregulation Syndrome in Parkinson's Disease.2025 · Sr Care Pharm · Other paper
- Analysis of amino acids in Mucuna pruriens supplements using hydrophilic interaction liquid chromatography-tandem mass spectrometry.2026 · Amino Acids · Other paper
- Mucuna pruriens Treatment for Parkinson Disease: A Systematic Review of Clinical Trials.2025 · Parkinsons Dis · Review
- "To Bean or Not to Bean": Therein lie the hype and the hope. Advice to people with Parkinson in my clinic about Mucuna pruriens.2026 · J Parkinsons Dis · Review
- Mucuna pruriens to treat Parkinson's disease in low-income countries: Recommendations and practical guidelines from the farmer to clinical trials. Paving the way for future use in clinical practice.2024 · Parkinsonism Relat Disord · Review
- Recovery of motor function is associated with rescue of glutamate biomarkers in the striatum and motor cortex following treatment with Mucuna pruriens in a murine model of Parkinsons disease.2023 · Mol Cell Neurosci · In animals
- Effects of Mucuna pruriens (L.) DC. and Levodopa in Improving Parkinson's Disease in Rotenone Intoxicated Mice.2024 · Curr Issues Mol Biol · In animals
- n-Propanol extract of boiled and fermented koro benguk (Mucuna pruriens seed) shows a neuroprotective effect in paraquat dichloride-induced Parkinson's disease rat model.2018 · Vet World · In animals
- Chitosan functionalized selenium nanoconjugates of Mucuna pruriens as a nanotherapeutic approach for Parkinson's disease.2026 · Discov Nano · In animals
- Levodopa-Reduced Mucuna pruriens Seed Extract Shows Neuroprotective Effects against Parkinson's Disease in Murine Microglia and Human Neuroblastoma Cells, Caenorhabditis elegans, and Drosophila melanogaster.2018 · Nutrients · In the lab
- Impact of Ayurvedic purification (Shodhana) on Mucuna pruriens for primary health care in Parkinson's disease: phytochemical profile, bioavailability of L-DOPA, and comparative UPLC-MS/MS QTOF-Caco-2 analysis.2026 · Front Med (Lausanne) · In the lab
- Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation of Mucuna pruriens for Parkinson's Disease Treatment.2026 · Curr Drug Targets · Other paper